Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$250.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ValiRx PLC Announces New Patent Grant For Therapeutic Compound


Thursday, 25 Apr 2013 02:00am EDT 

ValiRx PLC announced that a patent covering its therapeutic compound VAL201 has been granted in Australia. The original patent and technology covering VAL201 is licensed by ValiRx from Cancer Research Technology ("CRT") for use in androgen resistant cancer. The Company has all rights to perform pre-clinical and clinical developments and obtaining regulatory approvals in all territories. 

Company Quote

0.3695
0.0 +0.00%
3:36am EDT